Impact of Genetic Risk Factors for Alzheimer's Disease on Brain Glucose Metabolism

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2021 Jan 22

PMID 33479841

Citations 6

Authors

Sukhee Cho

Hyein Lee

Jinsoo Seo

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disease that affects more than 30 million people worldwide. Despite growing knowledge of AD pathophysiology, a complete understanding of the pathogenic mechanisms underpinning AD is lacking, and there is currently no cure for AD. Extant literature suggests that AD is a polygenic and multifactorial disease underscored by complex and dynamic pathogenic mechanisms. Despite extensive research and clinical trials, there has been a dearth of novel drugs for AD treatment on the market since memantine in 2003. This lack of therapeutic success has directed the entire research community to approach the disease from a different angle. In this review, we discuss growing evidence for the close link between altered glucose metabolism and AD pathogenesis by exploring how genetic risk factors for AD are associated with dysfunctional glucose metabolism. We also discuss modification of genes responsible for metabolic pathways implicated in AD pathology.

Citing Articles

Energy metabolism in health and diseases.

Liu H, Wang S, Wang J, Guo X, Song Y, Fu K Signal Transduct Target Ther. 2025; 10(1):69.

PMID: 39966374 PMC: 11836267. DOI: 10.1038/s41392-025-02141-x.

Regulatory Mechanisms and Therapeutic Implications of Lysosomal Dysfunction in Alzheimer's Disease.

Kim Y, Ha T, Lee M, Chang K Int J Biol Sci. 2025; 21(3):1014-1031.

PMID: 39897039 PMC: 11781173. DOI: 10.7150/ijbs.103028.

A multimodal Neuroimaging-Based risk score for mild cognitive impairment.

Zendehrouh E, Sendi M, Abrol A, Batta I, Hassanzadeh R, Calhoun V Neuroimage Clin. 2024; 45:103719.

PMID: 39637673 PMC: 11664180. DOI: 10.1016/j.nicl.2024.103719.

Towards a multimodal neuroimaging-based risk score for mild cognitive impairment by combining clinical studies with a large (N>37000) population-based study.

Zendehrouh E, Sendi M, Abrol A, Batta I, Hassanzadeh R, Calhoun V medRxiv. 2024; .

PMID: 38559205 PMC: 10980138. DOI: 10.1101/2024.03.12.24303873.

Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview.

Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L Cells. 2023; 12(16).

PMID: 37626828 PMC: 10453773. DOI: 10.3390/cells12162019.

References

Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618):50-6. DOI: 10.1038/nature19323. View

Sacks C, Avorn J, Kesselheim A . The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. N Engl J Med. 2017; 376(18):1706-1708. DOI: 10.1056/NEJMp1701047. View

Mosconi L . Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005; 32(4):486-510. DOI: 10.1007/s00259-005-1762-7. View

Weise C, Chen K, Chen Y, Kuang X, Savage C, Reiman E . Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. Neuroimage Clin. 2018; 20:286-296. PMC: 6084012. DOI: 10.1016/j.nicl.2018.07.016. View

Mosconi L, Mistur R, Switalski R, Tsui W, Glodzik L, Li Y . FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009; 36(5):811-22. PMC: 2774795. DOI: 10.1007/s00259-008-1039-z. View

Gordon B, Blazey T, Su Y, Hari-Raj A, Dincer A, Flores S . Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018; 17(3):241-250. PMC: 5816717. DOI: 10.1016/S1474-4422(18)30028-0. View

Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M . Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999; 65(3):664-70. PMC: 1377972. DOI: 10.1086/302553. View

Bellenguez C, Grenier-Boley B, Lambert J . Genetics of Alzheimer's disease: where we are, and where we are going. Curr Opin Neurobiol. 2019; 61:40-48. DOI: 10.1016/j.conb.2019.11.024. View

Kunkle B, Grenier-Boley B, Sims R, Bis J, Damotte V, Naj A . Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019; 51(3):414-430. PMC: 6463297. DOI: 10.1038/s41588-019-0358-2. View

10.

Dienel G . Brain Glucose Metabolism: Integration of Energetics with Function. Physiol Rev. 2018; 99(1):949-1045. DOI: 10.1152/physrev.00062.2017. View

11.

Schubert D . Glucose metabolism and Alzheimer's disease. Ageing Res Rev. 2005; 4(2):240-57. DOI: 10.1016/j.arr.2005.02.003. View

12.

de Leon M, Convit A, Wolf O, Tarshish C, DeSanti S, Rusinek H . Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001; 98(19):10966-71. PMC: 58582. DOI: 10.1073/pnas.191044198. View

13.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S . Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003; 30(8):1104-13. DOI: 10.1007/s00259-003-1194-1. View

14.

Mosconi L, Tsui W, Rusinek H, De Santi S, Li Y, Wang G . Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2007; 34(9):1467-79. DOI: 10.1007/s00259-007-0406-5. View

15.

Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I . Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain. 2009; 132(Pt 7):1820-32. PMC: 2702834. DOI: 10.1093/brain/awp099. View

16.

Wang D, Pascual J, Yang H, Engelstad K, Mao X, Cheng J . A mouse model for Glut-1 haploinsufficiency. Hum Mol Genet. 2006; 15(7):1169-79. DOI: 10.1093/hmg/ddl032. View

17.

Ullner P, Di Nardo A, Goldman J, Schobel S, Yang H, Engelstad K . Murine Glut-1 transporter haploinsufficiency: postnatal deceleration of brain weight and reactive astrocytosis. Neurobiol Dis. 2009; 36(1):60-9. PMC: 2929707. DOI: 10.1016/j.nbd.2009.06.014. View

18.

Simpson I, Chundu K, Honer W, Davies P . Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol. 1994; 35(5):546-51. DOI: 10.1002/ana.410350507. View

19.

Winkler E, Nishida Y, Sagare A, Rege S, Bell R, Perlmutter D . GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015; 18(4):521-530. PMC: 4734893. DOI: 10.1038/nn.3966. View

20.

Niccoli T, Cabecinha M, Tillmann A, Kerr F, Wong C, Cardenes D . Increased Glucose Transport into Neurons Rescues Aβ Toxicity in Drosophila. Curr Biol. 2016; 26(17):2291-300. PMC: 5026704. DOI: 10.1016/j.cub.2016.07.017. View